WOBURN, MASSACHUSETTS – Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today presented clinical results from a longer-term durability study of FX-322, showing that some patients with chronic sensorineural hearing loss had significant improvement in key measures of hearing that were sustained for up to 21 months.
Frequency Therapeutics Finds Sustained Improvement in Hearing Loss Patients Treated with FX-322
Sustained hearing improvement in patients treated with FX-322
American Buddhist Net 